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Résumé en
anglais
BACKGROUND: The optimum use of cytotoxic drugs for advanced colorectal
cancer has not been defined. Our aim was to investigate whether combination
treatment is better than the sequential administration of the same drugs in patients
with advanced colorectal cancer.
METHODS: In this open-label, randomised, phase 3 trial, we randomly assigned
patients (1:1 ratio) with advanced, measurable, non-resectable colorectal cancer and
WHO performance status 0-2 to receive either first-line treatment with bolus (400
mg/m(2)) and infusional (2400 mg/m(2)) fluorouracil plus leucovorin (400 mg/m(2))
(simplified LV5FU2 regimen), second-line LV5FU2 plus oxaliplatin (100 mg/m(2))
(FOLFOX6), and third-line LV5FU2 plus irinotecan (180 mg/m(2)) (FOLFIRI) or first-
line FOLFOX6 and second-line FOLFIRI. Chemotherapy was administered every 2
weeks. Randomisation was done centrally using minimisation (minimisation factors
were WHO performance status, previous adjuvant chemotherapy, number of disease
sites, and centre). The primary endpoint was progression-free survival after two
lines of treatment. Analyses were by intention-to-treat. This trial is registered at
ClinicalTrials.gov, NCT00126256.
FINDINGS: 205 patients were randomly assigned to the sequential group and 205
to the combination group. 161 (79%) patients in the sequential group and 161 (79%)
in the combination group died during the study. Median progression-free survival
after two lines was 10·5 months (95% CI 9·6-11·5) in the sequential group and 10·3
months (9·0-11·9) in the combination group (hazard ratio 0·95, 95% CI 0·77-1·16;
p=0·61). All six deaths caused by toxic effects of treatment occurred in the
combination group. During first-line chemotherapy, significantly fewer severe (grade
3-4) haematological adverse events (12 events in 203 patients in sequential group vs
83 events in 203 patients in combination group; p<0·0001) and non-haematological
adverse events (26 events vs 186 events; p<0·0001) occurred in the sequential
group than in the combination group.
INTERPRETATION: Upfront combination chemotherapy is more toxic and is not
more effective than the sequential use of the same cytotoxic drugs in patients with
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